Company Overview

Vivani Medical, Inc. (NASDAQ: VANI) is a clinical-stage biopharmaceutical company focused on developing long-acting implantable drug delivery technologies for the treatment of chronic diseases. The company operates within the biotechnology and medical device–enabled therapeutics industries, with a strategic emphasis on metabolic and endocrine disorders. Vivani’s core objective is to improve treatment adherence and outcomes by replacing frequent injections or daily oral therapies with ultra-long-duration subdermal implants.

The company’s primary revenue drivers are currently research and development activities, as Vivani does not yet generate commercial product revenue. Its lead product candidates are based on its proprietary NanoPortal™ implant technology, designed to deliver therapeutic drug levels continuously for six months or longer. Vivani primarily targets patients with chronic conditions such as obesity and type 2 diabetes, where medication adherence is a persistent clinical challenge. The company positions itself uniquely by combining drug formulation with precision implant technology to compete in markets currently dominated by injectable therapies.

Vivani Medical was formed in 2022 through the merger of Second Sight Medical Products, Inc. and Nano Precision Medical, Inc., following a strategic restructuring and recapitalization. The transaction shifted the company’s focus away from ophthalmic devices toward long-duration drug implants, rebranding the combined entity as Vivani Medical, Inc.

Business Operations

Vivani operates as a single-reportable segment focused on the research, development, and eventual commercialization of implantable therapeutics. Its core business activities center on advancing clinical-stage product candidates using the NanoPortal™ platform, which consists of a miniature titanium implant engineered for controlled and sustained drug release. The company’s most advanced programs include NPM-115 (semaglutide implant) and NPM-139 (exenatide implant), both aimed at metabolic diseases.

Operations are primarily based in the United States and include preclinical research, clinical trial management, regulatory strategy, and manufacturing process development. Vivani controls its implant design, drug formulation processes, and intellectual property portfolio internally. The company operates through its wholly owned subsidiary Nano Precision Medical, Inc., which holds key platform technology assets and development operations. As of the most recent public disclosures, Vivani does not report material revenue from partnerships or licensing arrangements.

Strategic Position & Investments

Vivani’s strategic direction centers on becoming a leader in long-acting implantable therapeutics for large chronic disease markets. Growth initiatives focus on advancing lead candidates through clinical development, expanding the application of the NanoPortal™ technology to additional drug molecules, and pursuing regulatory pathways in the United States. The company prioritizes metabolic diseases due to large patient populations, strong market demand, and established efficacy of GLP-1–based therapies.

Major investments have been directed toward clinical trials, manufacturing scale-up capabilities, and intellectual property protection. The formation of Vivani itself represents a transformative strategic transaction, consolidating assets from Second Sight Medical Products, Inc. and Nano Precision Medical, Inc. into a single platform-focused company. Vivani has indicated interest in emerging drug-delivery technologies and combination product development, though specific future acquisitions or external investments have not been conclusively disclosed in public filings.

Geographic Footprint

Vivani Medical is headquartered in the United States, with principal operations in California. Its research, development, and corporate functions are primarily domestic, reflecting its current clinical-stage status. The company’s manufacturing development and clinical trial activities are also largely U.S.-based, leveraging domestic regulatory expertise and infrastructure.

While Vivani does not yet have significant international commercial operations, its therapeutic focus addresses global disease markets, and its long-term strategy contemplates broader geographic reach pending regulatory approvals. International influence is currently limited to potential future clinical trials and regulatory planning outside the U.S., with no material foreign subsidiaries reported in public disclosures.

Leadership & Governance

Vivani is led by an executive team with experience in biotechnology, medical devices, and public company governance. The leadership emphasizes disciplined capital allocation, platform scalability, and regulatory rigor as core elements of its strategic vision. Governance is structured around a publicly traded company framework, with oversight from a board of directors following the company’s merger and reorganization.

Key executives include:

• Adam Mendelsohn – Chief Executive Officer
• Justin Mader – Chief Financial Officer
• Jackie L. Reese – Chief Operating Officer
• David M. Fischel – Chief Medical Officer

The leadership team has articulated a strategy focused on transforming chronic disease management through long-duration implantable therapies, with an emphasis on patient adherence, clinical differentiation, and long-term value creation.

Verification Requirements

All information presented is derived from publicly available company disclosures, including SEC filings, investor presentations, and coverage by major financial and biotechnology publications. Where details regarding future plans, partnerships, or international expansion lack sufficient confirmation, the information is presented conservatively. If specific data points could not be verified consistently across independent sources, they are treated as non-conclusive based on available public sources.